Effect of paracetamol in gastrointestinal cancer surgery

Comparison the effect of paracetamol and pethedine in reducing opioid consumption and pain scale in patients under gastrointestinal tract malignancies surgery.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201207283305N4

Enrollment

Registered

2017-08-14

Start date

2012-07-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Gastrointestinal Malignancies. Condition 2: Gastrointestinal Malignancies. Condition 3: Gastrointestinal Malignancies. Condition 4: Gastrointestinal Malignancies. Malignant neoplasm of stomach Malignant neoplasm of small intestine Malignant neoplasm of colon Malignant neoplasm of oesophagus

Interventions

Intervention 1: Intervention group: every 6 hours up to a maximum weight based on grams (total dose 24 h 4 grams) Paracetamol IV to receive. If a patient requires drug for pain or analgesic PRN 0.5mg/

Treatment - Drugs

Intervention group: every 6 hours up to a maximum weight based on grams (total dose 24 h 4 grams) Paracetamol IV to receive. If a patient requires drug for pain or analgesic PRN 0.5mg/kg, up to a maxi

Control group: patients, 0.5mg/kg every 6 hours, up to a maximum of 50 mg analgesic receives and the need for additional drug fixed dose of 35 mg intravenously has analgesic.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: ASA class I-III; patient whom candidates GI Malignancy surgery and are hospitalized in ICU ward after surgery. Exclusion criteria: A History of sensitivity to paracetamol; kidney disease (end stage); liver disease or more than two times increase in the liver enzymes; severe malnutrition or dehydration; alcohol users; Recipients Recipients probensid, Salyslamyd or drugs that are induce liver enzymes.Severe drop in blood pressure during or after, severe dyspnea requiring respiratory support, severe thrombocytopenia, decreased level of consciousness.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Reduce pain. Timepoint: Three days after surgery. Method of measurement: VAS.	—

Secondary

Measure	Time frame
Nausea & Vomiting. Timepoint: Three days after surgery. Method of measurement: Visual and questional.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ebrahim Alijanpour

Babol University of Medical Sciences

dralijanpour@yahoo.com; ans_dep@yahoo.com+98 11 1223 8296

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026